Target: CTLA-4
Ipilimumab
- IgG1κ anti-CTLA4 mAb
- FDA 2011 for non-resectable stage III/IV melanoma.
Less impressive results in RCC, NSCLC, SCLC, prostate ca.
Tremelimumab
- IgG2 anti-CTLA4 mAb
- yet to receive FDA approval for melanoma (no survival gain)
Your cart (items: 0)
Subtotal
$0.00
Shipping and discounts calculated at checkout.
Your cart is currently empty!